Neoplasm, Residual

"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Remnant of a tumor or cancer after primary, potentially curative therapy.

Descriptor ID	D018365
MeSH Number(s)	C04.697.700 C23.550.727.700
Concept/Terms	Neoplasm, Residual Neoplasm, Residual Residual Neoplasms Residual Neoplasm Minimal Residual Disease Minimal Disease, Residual Residual Minimal Disease Residual Minimal Diseases Residual Disease, Minimal Minimal Residual Diseases Residual Cancer Residual Cancer Cancer, Residual Residual Cancers Residual Tumor Residual Tumor Residual Tumors Residual Tumour Residual Tumours Tumour, Residual

Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".

Diseases [C]
Neoplasms [C04]
Neoplastic Processes [C04.697]
Neoplasm, Residual [C04.697.700]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Neoplastic Processes [C23.550.727]
Neoplasm, Residual [C23.550.727.700]

Below are MeSH descriptors whose meaning is related to "Neoplasm, Residual".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.

Bar chart showing 26 publications over 16 distinct years, with a maximum of 2 publications in 2002 and 2004 and 2005 and 2008 and 2009 and 2010 and 2013 and 2014 and 2018 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	1	2
2003	0	1	1
2004	0	2	2
2005	0	2	2
2008	0	2	2
2009	0	2	2
2010	1	1	2
2011	0	1	1
2013	0	2	2
2014	1	1	2
2015	0	1	1
2016	0	1	1
2018	2	0	2
2020	1	1	2
2021	0	1	1
2022	0	1	1

Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.

Arisi MF, Dotan E, Fernandez SV. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. Int J Mol Sci. 2022 Apr 18; 23(8).

View in: PubMed
Lanahan CR, Kelly BN, Gadd MA, Specht MC, Brown CL, Hughes KS, Tang R, Rai U, Brachtel EF, Rice-Stitt T, Smith BL. Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery. Breast Cancer Res Treat. 2021 May; 187(1):145-153.

View in: PubMed
Germans SK, Kulak O, Koduru P, Oliver D, Gagan J, Patel P, Anderson LD, Fuda FS, Chen W, Jaso JM. Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity. Am J Clin Pathol. 2020 11 04; 154(6):816-827.

View in: PubMed
Smith BL, Lanahan CR, Specht MC, Kelly BN, Brown C, Strasfeld DB, Ferrer JM, Rai U, Tang R, Rice-Stitt T, Biernacka A, Brachtel EF, Gadd MA. Feasibility Study of a Novel Protease-Activated Fluorescent Imaging System for Real-Time, Intraoperative Detection of Residual Breast Cancer in Breast Conserving Surgery. Ann Surg Oncol. 2020 Jun; 27(6):1854-1861.

View in: PubMed
Smith BL, Gadd MA, Lanahan CR, Rai U, Tang R, Rice-Stitt T, Merrill AL, Strasfeld DB, Ferrer JM, Brachtel EF, Specht MC. Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system. Breast Cancer Res Treat. 2018 Sep; 171(2):413-420.

View in: PubMed
Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018 04 24; 2(8):825-831.

View in: PubMed
Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176.

View in: PubMed
Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015 Mar 10; 33(8):937-43.

View in: PubMed
Tang R, Coopey SB, Specht MC, Lei L, Gadd MA, Hughes KS, Brachtel EF, Smith BL. Lumpectomy specimen margins are not reliable in predicting residual disease in breast conserving surgery. Am J Surg. 2015 Jul; 210(1):93-8.

View in: PubMed
Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL. Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. Am J Surg Pathol. 2014 Mar; 38(3):333-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement